Cargando…

Targeting the guanine-based purinergic system in Alzheimer's disease

Detalles Bibliográficos
Autores principales:	Lanznaster, Débora, Tasca, Carla I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2017
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5361501/ https://www.ncbi.nlm.nih.gov/pubmed/28400799 http://dx.doi.org/10.4103/1673-5374.200801

Ejemplares similares

Neuromodulatory Effects of Guanine-Based Purines in Health and Disease
por: Tasca, Carla I., et al.
Publicado: (2018)

The Guanine-Based Purinergic System: The Tale of An Orphan Neuromodulation
por: Di Liberto, Valentina, et al.
Publicado: (2016)

Purinergic signalling in neuroregeneration
por: Burnstock, Geoffrey
Publicado: (2015)

Contribution of purinergic receptors to spinal cord injury repair: stem cell-based neuroregeneration
por: Gomez-Villafuertes, Rosa
Publicado: (2016)

Trichomoniasis immunity and the involvement of the purinergic signaling
por: Menezes, Camila Braz, et al.
Publicado: (2016)

Guanosine: a Neuromodulator with Therapeutic Potential in Brain Disorders
por: Lanznaster, Débora, et al.
Publicado: (2016)

Mitochondrial Localization and Function of the Purinergic Receptor P2X(7)
por: Kroemer, Guido, et al.
Publicado: (2021)

Role of purinergic receptors in the Alzheimer’s disease
por: Cieślak, Marek, et al.
Publicado: (2018)

Heparan sulfate proteoglycans and heparanases in Alzheimer's disease: current outlook and potential therapeutic targets
por: Lorente-Gea, Laura, et al.
Publicado: (2017)

Neuroprotection induced by NMDA preconditioning as a strategy to understand brain tolerance mechanism
por: Constantino, Leandra C., et al.
Publicado: (2015)

Dual targeting nano-approaches for Alzheimer's disease etiology
por: Hettiarachchi, Sajini D., et al.
Publicado: (2020)

Targeting the transferrin receptor to develop erythropoietin for Alzheimer's disease
por: Sumbria, Rachita K.
Publicado: (2020)

Targeting immunometabolic pathways for combination therapy in Alzheimer's disease
por: Erichsen, Jennifer, et al.
Publicado: (2023)

TREM2 as an evolving therapeutic target in Alzheimer’s disease
por: George, Jacob
Publicado: (2023)

Emerging small-molecule therapeutic approaches for Alzheimer's disease and Parkinson's disease based on targeting microRNAs
por: Abdelrahman, Somaya A., et al.
Publicado: (2021)

Targeting abnormal metabolism in Alzheimer's disease: The Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study
por: Desai, Rishi J., et al.
Publicado: (2020)

NLRP3 inflammasome couples purinergic signaling with activation of the complement cascade for the optimal release of cells from bone marrow
por: Ratajczak, Mariusz Z., et al.
Publicado: (2019)

Lingo-1: a novel target in therapy for Alzheimer's disease?
por: Fernandez-Enright, Francesca, et al.
Publicado: (2016)

Unfolding New Roles for Guanine-Based Purines and Their Metabolizing Enzymes in Cancer and Aging Disorders
por: Di Iorio, P., et al.
Publicado: (2021)

Caveolae, CD109, and endothelial cells as targets for treating Alzheimer's disease
por: Fessel, Jeffrey
Publicado: (2020)

Neurovascular ageing: transcriptomic readout and implications on therapeutic targeting in Alzheimer's disease
por: Li, Zhongqi, et al.
Publicado: (2021)

CD34(+) progenitor cells as diagnostic and therapeutic targets in Alzheimer’s disease
por: Romaus-Sanjurjo, Daniel, et al.
Publicado: (2022)

Is EAAT2 a potential therapeutic intervention target for Alzheimer’s disease?
por: Wood, Oliver WG, et al.
Publicado: (2023)

Targeting calcium signaling in Alzheimer’s disease: challenges and promising therapeutic avenues
por: Song, LinLin, et al.
Publicado: (2023)

Local elementary purinergic-induced Ca(2+) transients: from optical mapping of nerve activity to local Ca(2+) signaling networks
por: Hill-Eubanks, David C., et al.
Publicado: (2010)

Tetrahydrohyperforin: a neuroprotective modified natural compound against Alzheimer's disease
por: Montecinos-Oliva, Carla, et al.
Publicado: (2015)

The seeming paradox of adenosine receptors as targets for the treatment of Alzheimer's disease: agonists or antagonists?
por: Marzagalli, Rubina, et al.
Publicado: (2015)

APOE targeting strategy in Alzheimer’s disease: lessons learned from protective variants
por: Bu, Guojun
Publicado: (2022)

Alzheimer's disease diagnosis and management: Perspectives from around the world
por: Kerwin, Diana, et al.
Publicado: (2022)

Vascular dysfunction in Alzheimer’s disease: a biomarker of disease progression and a potential therapeutic target
por: Govindpani, Karan, et al.
Publicado: (2019)

Chitosan-based nanoparticles in Alzheimer’s disease: messenger or message?
por: Manek, Eniko, et al.
Publicado: (2021)

Preventative medicine and Alzheimer’s disease: is Alzheimer’s disease risk reduction achievable?
por: Sinyor, Benjamin, et al.
Publicado: (2021)

Is it time to rethink the Alzheimer's disease drug development strategy by targeting its silent phase?
por: Souchet, Benoit, et al.
Publicado: (2018)

Acid-sensing ion channel 1a: a novel target in Alzheimer’s disease?
por: Mango, Dalila, et al.
Publicado: (2022)

Detection and clearance in Alzheimer’s disease: leading with illusive chemical, structural and morphological features of the targets
por: Gales, Luís
Publicado: (2023)

Purinergic Signaling and Cochlear Injury-Targeting the Immune System?
por: Köles, László, et al.
Publicado: (2019)

Targeting the purinergic pathway in breast cancer and its therapeutic applications
por: de Araújo, Julia Beatrice, et al.
Publicado: (2021)

Open drug discovery in Alzheimer's disease
por: Axtman, Alison D., et al.
Publicado: (2023)

Alzheimer and Purinergic Signaling: Just a Matter of Inflammation?
por: Merighi, Stefania, et al.
Publicado: (2021)

Heparan sulfate proteoglycans as possible diagnostic molecular tools with therapeutic potential in Alzheimer´s disease
por: Fernández-Vega, Iván, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_925n1dhbr0jnhhk0dprg0d2vbt